Welcome : Guest

Compugen Ltd. (Israel) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Compugen Ltd., which is principally a Therapeutic Discovery Company. Illustrated with 144 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-32750
Price: $3500
Company Type: Public
Pages: 145
Date: January 2017
Market Data Tables: 144

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: Compugen Ltd.’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for Israel, and Europe......2
Table 2: Compugen Ltd.’s Sales by Geographic Region Worldwide (2013-2014) in Percentage for Israel and Europe......3
Speciality Pharmaceuticals......4
Table 3: Speciality Pharmaceuticals Market by Category in the US (2015) - Percentage Share Breakdown by Value Sales for Anti-Coagulant, Growth Hormone, Hepatitis C, HIV/AIDS (incl oral solids), IVIG/Hemophilia, Macular Degeneration, Multiple Sclerosis, Oncology (incl. oral solids), Pulmonary Arterial Hypertension, Renal, Rheumatoid arthritis/Chrohn's, Transplant, and Others......4
Table 4: Specialty Pharmaceuticals Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Hepatitis, HIV & AIDS (including oral solids), Intravenous Immunoglobulin (Hemophilia), Multiple Sclerosis, Oncology (including oral solids), Renal, Rheumatoid Arthritis (Crohn's), and Others......5
Cancer Drugs......6
Table 5: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......6
Table 6: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......7
Cancer Market......8
Table 7: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......8
Table 8: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......9
Table 9: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......10
Table 10: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......11
Table 11: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......12
Table 12: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......13
Table 13: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......14
Table 14: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......15
Cancer Patients......16
Table 15: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......16
Table 16: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......17
Table 17: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......18
Table 18: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......19
Table 19: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......20
Table 20: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......21
Table 21: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......22
Table 22: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......23
Table 23: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......24
Table 24: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......25
Table 25: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......26
Table 26: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......27
Table 27: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......28
Table 28: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......29
Table 29: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......30
Table 30: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......31
Table 31: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......32
Table 32: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......33
Table 33: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......34
Table 34: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......35
Table 35: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......36
Cervical Cancer......37
Table 36: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......37
Table 37: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......38
Hematological Cancer......39
Table 38: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......39
Skin Cancer......40
Table 39: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......40
Cancer-Associated Mucositis......41
Table 40: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......41
Chronic Myelogenous Leukemia (CML)......42
Table 41: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......42
Multiple Myeloma......43
Table 42: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......43
Table 43: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......44
Non Hodgkin lymphoma (NHL)......45
Table 44: Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Rituxan, Gazyva, and Others......45
Table 45: Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Volume for Burkitt Lymphoma-Burkitt Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Immunodeficiency-Associated Lymphoproliferative Disorders, Lymphoplasmacytic Lymphoma, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma, Small Cell Lymphocytic Lymphoma-Chronic Lymphocytic Leukemia, T-Cell and Natural Killer (NK)-Cell Lymphoma, and Others......46
Table 46: Indolent Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Rituxan, Gazyva, and Others......47
Table 47: No. of Non Hodgkin lymphoma (NHL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......48
Table 48: No. of Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......49
Table 49: No. of Indolent Non Hodgkin lymphoma (NHL) (1L) Patients by Category in European Union (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......50
Table 50: No. of Indolent Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in European Union (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......51
Table 51: No. of Non Hodgkin lymphoma (NHL) Patients by Category in the US (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......52
Table 52: No. of Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in the US (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......53
Table 53: No. of Indolent Non Hodgkin lymphoma (NHL) (1L) Patients by Category in the US (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......54
Table 54: No. of Indolent Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in the US (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......55
Diabetes......56
Table 55: Diabetes Market by Region Worldwide (2015) - Percentage Share Breakdown for Africa, Europe, Middle East & North Africa, North America & Caribbean, Southeast Asia, and Western Pacific......56
Table 56: Diabetes Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Insulin Type‐1 Diabetes, Insulin Type‐2 Diabetes, Dipeptidyl Peptidase 4, (DPP4), Glucagon-like Peptide-1 (GLP‐1), Dipeptidyl Peptidase 4, (DPP4) + Biguanide, and Others* (includes Sodium-Glucose Co-Transporter-2 (SGLT2), Biguanide, Sulfonylurea, Alpha-Glucosidase Inhibitors, Peroxisome Proliferator-Activated Receptor (PPAR)......57
Table 57: Diabetes Care Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Human Insulins, Modern Insulins, Victoza, and Others......58
Table 58: Type-II Diabetes Treatments Market Worldwide (2015-2020) in US$ Million......59
Table 59: Type II Diabetes Market by Treatment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-IV Inhibitors, GLP-1 Agonists, SGLT-2 Inhibitors and Thiazolidinediones......60
Table 60: Type II Diabetes Market by Insulin Treatment Worldwide (2015) - Percentage Share Breakdown by Value for Diet and Exercise Only, Insulin and Orals and Insulin Only......61
Table 61: Diabetes Healthcare Market by Category in the US (2015) - Percentage Share Breakdown by Value for Anti -Diabetic Agents & Supplies, Doctor Office Visits, Hospital Care, Nursing/Residential Facility Stays, Prescription Medication, and Others......62
Table 62: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown for Insulin Pumps, and Multiple Daily Injections......63
Table 63: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown by Value for Type 1, and Type 2......64
Table 64: No. of Diabetes Patients by Medication in the US (2015) - Percentage Share Breakdown for Insulin and Oral Medication, Insulin Only, No Medication, and Oral Medication Only......65
Diabetes Drugs......66
Table 65: Diabetes Drug Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-4 Inhibitor, GK Activator, GLP-1 Agonist, GPCR Agonist, IL- Receptor Antagonist, Insulin Analogue, PPAR Agonist, SGLT-2 Inhibitor, and Others......66
Table 66: Diabetes/Metabolic Drugs Market by Category Worldwide (2015) - Percentage Breakdown by Value Sales for DPP-IV Inhibitors, Glitazones, GLP-1 Analogs, Insulins, Sulfonylureas, and Others......67
Table 67: Anti-Diabetic Drug Market by Treatment Class Worldwide (2015) - Percentage Share Breakdown by Value for Diet & Exercise, Incretion, Insulin and Oral Anti-Diabetic......68
Table 68: Antidiabetes Molecules Market by Drug Worldwide (2015) - Percentage Share Breakdown by Value for Metformin, Sulfonylureas, Thiazolidin Ediones and Others......69
Table 69: Anti-Diabetic Drugs Market in China (2015-2020) in RMB Million......70
Table 70: Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glinide, Insulin, Sulfonylureas, α-glucosidase Inhibitor, and Others......71
Table 71: Anti-Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Insulin Drugs and Non-Insulin Drugs......72
Table 72: Diabetes Drugs Market by Product Category in China (2015) - Percentage Share Breakdown by Value for Acarbose, Insulin, Melbine, and Other Diabetes Drugs......73
Table 73: Diabetic Drugs Market by Category in the US (2015) - Percentage Share Breakdown by Value for DPP-IV & SGLT-2, GLP-1, Insulins, and Others......74
Table 74: Diabetic Drugs Market by Non-Insulin Therapy in the US (2015) - Percentage Share Breakdown by Volume for Biguanides, DPP-4 Inhibitor, Human GLP-1 Analogs, SGLT-2 Inhibitor, Sulfonylureas, and Others......75
Table 75: Oral Diabetes Medicine Market in the US (2015) - Percentage Share Breakdown by Value Sales for Dipeptidyl Peptidase-4 (DPP4), Metformin, Sulfonylureas, and Others......76
Non-Insulin Anti-Diabetic Drugs......77
Table 76: Non-Insulin Anti-Diabetic Drugs Market by Product in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glucosidase Inhibitors, Nateglinide, Sulfonylurea and Others......77
Diabetic Macular Edema (DME)......78
Table 77: Diabetic Macular Edema (DME) Market by Drug Treatment Worldwide (2015) - Percentage Share Breakdown by Volume for Avastin, Laser Photocoagulation, Lucentis 0.3 mg, Steroids and Others......78
Table 78: Diabetic Macular Edema (DME) Anti Vascular Endothelial Growth Factor (VEGF) Market by Segment in the US (2015) - Percentage Share Breakdown by Volume for Avastin, Lucentis and Others......79
Insulin......80
Table 79: Insulin Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Aspart (Novolog), Detemir (Levemir), Glargine (Lantus), Glulisine (Apidra), Lispro (Humalog), and Rh Insulin......80
Table 80: Insulin Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Basal Insulins, Prandial Insulins and Pre-Mixed Insulin......81
Table 81: Insulin Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Fast Acting, Long Acting and Premix......82
Table 82: Insulin Market by Generation in China (2015) - Percentage Share Breakdown by Value for 1st Generation, 2nd Generation, and 3rd Generation......83
Table 83: Insulin Market by Product Type in the US (2015) - Percentage Share Breakdown by Value for Fast-Acting, Human, Long-Acting and Mix......84
DPP-4 Inhibitors......85
Table 84: DPP-4 Inhibitors Market by Product Category Worldwide (2015) - Percentage Share Breakdown by Value for Galvus & Galvumet (Novartis), Januvia & Janumet (MRK), Nesina & Kezano (Takeda), Onglyza & Kombiglyze (AZN/BMY) and Tradjenta & Jentadueto (BI/Lilly)......85
Table 85: DPP-4 Inhibitors Market in China (2015-2020) in RMB Million......86
Table 86: DPP-4 Inhibitors (Fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Galvusmet, Janumet, Janumet XR, Kombiglyze, Trajenta Duo and Zemimet......87
Table 87: DPP-4 Inhibitors (Non-fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Januvia, Nesina, Tradjenta, Zemiglo, and Others......88
Table 88: DPP-4 Inhibitors Market by Prescription in the US (2015) - Percentage Share Breakdown by Volume for Janumet (Sitagliptin + Metformin), Januvia (Sitagliptin), Kombiglyze XR (Saxagliptin + Metformin), Onglyza (Saxagliptin), and Others......89
Table 89: DPP-4 Inhibitors Market in the US (2015) in No. of Prescriptions......90
DPP-4 type Diabetes Drugs......91
Table 90: DPP-4 type Diabetes Drugs Market in Japan (2015) in Yen Million......91
Multiple Sclerosis......92
Table 91: Multiple Sclerosis Disease Occurrence by Type Worldwide (2015) - Percentage Breakdown by Volume for Begin MS, Primary Progressive MS, Relapsing-Remiting MS, and Secondary Progressive MS......92
Table 92: Multiple Sclerosis Patient Care Expenditure by Category Worldwide (2015) - Percentage Breakdown by Value for Adaptations, Ambulatory Care, Disease Modifying Drugs, Early Retirement, Hospital Inpatient Care, Informal Care, Prescription and OTC Drugs, Services, Sick-leave and Redused Working Time, and Tests......93
Table 93: Relapsing-Remitting Multiple Sclerosis (RRMS) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union (EU), US, Rest of World (RoW)......94
Table 94: No. of Tcelna (Imilecleucel-T) Secondary Progressive Multiple Sclerosis Patients by Category in the US (2015) - Percentage Breakdown for Primary Progressive MS Patients, Relapsing-Remitting MS Patients, and Secondary-Progressive MS Patients......95
Psoriasis......96
Table 95: Psoriasis Disease by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Palmoplantar Psoriasis, Plaque Psoriasis, Psoriasis of Mucous Membranes, Psoriatic Arthritis, and Pustular Psoriasis......96
Infectious Disease Drugs......97
Table 96: Infectious Disease Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Molecular Diagnostics Infectious Diseases, and Others......97
Table 97: Infectious Disease Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antifungals, Antivirals, Cephalosporins, Macrolides, Penicillins, Quinolones, and Others......98
Monoclonal Antibodies......99
Table 98: Monoclonal Antibodies Market by Drugs Worldwide (2015) - Percentage Share Breakdown by Value for Avastin, Crestor, Enbrel, Humira, Lantus, Remicade and Others......99
Table 99: Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Biologics, Monoclonal Antibodies and Other Classes......100
Table 100: Therapeutic Biologics Market by Type in China (2015) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Granulocyte Colony-Stimulating Factor (GCSF), Insulin, Interferon, Interleukin, Monoclonal Antibodies (MAb), Nerve GF, Somatropin, and Others......101
Rheumatoid Arthritis......102
Table 101: Rheumatoid Arthritis Market by Product Type Worldwide (2015) - Percentage Share Breakdown by Value Sales for ENBREL, HUMIRA, REMICADE, and Others......102
Antivirals......103
Table 102: Antiviral Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others......103
Cancer Drugs......104
Table 103: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......104
Table 104: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......105
Table 105: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......106
Table 106: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......107
Table 107: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......108
Breast Cancer Drugs......109
Table 108: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......109
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......110
Table 109: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......110
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......111
Table 110: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......111
Table 111: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......112
Relapsed/Refractory (RR) Aggressive Non-Hodgkin Lymphoma (aNHL)......113
Table 112: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Aggressive Non-Hodgkin Lymphoma (aNHL) in the US (2015) - Percentage Breakdown by Value for ABT-199, Ibrutinib, Idelalisib, and Others......113
Diabetes Drugs......114
Table 113: Market Shares of Leading Diabetes Care Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Bristol-Myers Squibb (Incl Amylin), Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi S.A. and Others......114
Table 114: Market Shares of Leading Diabetes Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......115
Table 115: Market Shares of Leading Anti-Diabetic Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Abbott Healthcare Pvt Ltd., Biocon Limited, Lupin Pharmaceuticals, Inc., MSD Pharmaceuticals Private Limited, Sanofi-Aventis Groupe, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., and Others......116
Insulin......117
Table 116: Market Shares of Leading Insulin Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Others......117
Table 117: Market Shares of Leading Insulin Companies Worldwide (2014) - Percentage Breakdown by Volume Sales for Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Others......118
Table 118: Market Shares of Leading Fast & Intermediate Type Insulin Producers Worldwide (2015) - Percentage Share Breakdown by Value for Eli Lilly and Company, Novo Nordisk, Sanofi S.A. and Others......119
Table 119: Market Shares of Leading Long-Acting Insulin Producing Companies Worldwide (2015) - Percentage Share Breakdown by Value for Sanofi S.A., Wockhardt Ltd., and Others......120
Table 120: Market Shares of Leading Insulin Companies in China (2014) - Percentage Share Breakdown by Value for Eli Lilly and Company, GanLee Pharmaceutical Co., Ltd., Novo Nordisk, Sanofi S.A., Shanghai Fosun Pharmaceutical Group Co., Ltd., United Laboratories International Holdings Ltd. (The), Tonghua Dongbao Pharmaceutical Co., Ltd., and Others......121
Table 121: Market Shares of Leading Insulin Companies in China (2015) - Percentage Share Breakdown by Volume for Novo Nordisk, Tonghua Dongbao Pharmaceutical Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Others......122
Table 122: Market Shares of Leading Insulin Companies in Europe (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......123
Table 123: Market Shares of Leading Insulin Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Biocon Ltd., Cadila Pharmaceuticals Ltd., Eli Lilly and Company India Pvt. Ltd., Lupin Pharmaceuticals, Inc., Novo Nordisk India Ltd., Pfizer India Ltd., Ranbaxy Laboratories Ltd., Sanofi India Ltd., Shreya Life Sciences Pvt. Ltd., USV Ltd., and Wockhardt Ltd.......124
Table 124: Market Shares of Leading Insulin Companies in Japan and Korea (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......125
Table 125: Market Shares of Leading Insulin Companies in North America (2014) - Percentage Breakdown by Volume Sales for Novo Nordisk A/S, and Others......126
Second-Generation Insulin......127
Table 126: Market Shares of Leading Second-Generation Insulin Companies in China (2014) - Percentage Share Breakdown by Volume for Eli Lilly and Company, Novo Nordisk, The United Laboratories International Holdings, Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd.......127
Third-Generation Insulin......128
Table 127: Market Shares of Leading Third-Generation Insulin Companies in China (2014) - Percentage Share Breakdown by Volume for Eli Lilly and Company, Gan & Lee Pharmaceutical, Ltd., Novo Nordisk, and Sanofi S.A.......128
Human Insulin......129
Table 128: Market Shares of Leading Human Insulin Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Biocon Limited, Eli Lilly and Company India Pvt. Ltd., Novo Nordisk India Limited, Sanofi India Limited, Wockhardt Ltd., and Others......129
DPP-4 Inhibitors......130
Table 129: Market Shares of Leading DPP-4 Inhibitors Manufacturers by Value Sales Worldwide (2015) - Percentage Share Breakdown for Merck & Co., Inc. (Januvia/Janumet), Novartis AG (Galvus/Galvumet) and Takeda Pharmaceutical Co., Ltd. (Nesina/Kezano), and Others......130
Table 130: Market Shares of Leading DPP-4 Inhibitors for Treatment of Diabetes in Japan (2015) - Percentage Share Breakdown by Value for Equa, Glactiv, Januvia, Nesina, and Others......131
Table 131: Market Shares of Leading DPP-4 Drug Brands in China (2015) - Percentage Share Breakdown by Value for Galvus, Januvia, Onglyza, and Others......132
Sitagliptin/Metformin......133
Table 132: Market Shares of Leading Sitagliptin Brands by Value Sales in India (2015) - Percentage Share Breakdown for Istavel and Januvia......133
Table 133: Market Shares of Leading Sitagliptin Manufacturers by Value Sales in India (2015) - Percentage Share Breakdown for Merck & Co., Inc. and Sun Pharmaceutical Industries Ltd.......134
Table 134: Market Shares of Leading Sitagliptin/Metformin Brands by Value Sales in India (2015) - Percentage Share Breakdown for Janumet, and Others......135
Table 135: Market Shares of Leading Sitagliptin/Metformin Manufacturers by Value Sales in India (2015) - Percentage Share Breakdown for Merck & Co., Inc., and Others......136
Metformin......137
Table 136: Market Shares of Leading Metformin Suppliers in India (2015) - Percentage Share Breakdown by Value for Harman Finochem Ltd., USV Pharmaceuticals Ltd., Wanbury Limited and Others......137
Multiple Sclerosis......138
Table 137: Market Shares of Leading Multiple Sclerosis Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Biogen Idec, Novartis AG, Sanofi S.A., and Others......138
Table 138: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by No. of Patients for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......139
Table 139: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by Value for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......140
Psoriasis......141
Table 140: Market Shares of Leading Drugs for Treatment of Psoriasis Worldwide (2015) - Percentage Share Breakdown by Value for Enbrel, Humira, Remicade, Stelara and Others......141
Immunology......142
Table 141: Market Shares of Leading Immunology/ Immunoglobulin Providers in the US (2015) - Percentage Breakdown by Value for Baxter International Inc., CSL Limited, Grifols, S.A., and Others......142
Infectious Disease Drugs......143
Table 142: Market Shares of Leading Infectious Disease Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol- Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......143
Monoclonal Antibodies......144
Table 143: Market Shares of Leading Monoclonal Antibody Production Companies in the US (2015) - Percentage Share Breakdown by Value for Abbvie Inc., AMGen, Johnson & Johnson, F. Hoffmann-La Roche AG and Others......144
Table 144: Market Shares of Leading Primary Antibody Suppliers in the US (2015) - Percentage Share Breakdown by Value for Abcam plc, Cell Signaling Technology, Inc., Thermo Fisher Scientific Corporation, Santa Cruz Biotechnology, Inc., Sigma-Aldrich Corporation and Others......145